Futura Medical Share Chat (FUM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Futura Medical Plc	LSE:FUM	London	Ordinary Share	GB0033278473	ORD 0.2P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+1.25p	+5.15%	25.50p	25.00p	26.00p	25.50p	24.00p	24.25p	433,432	16:24:14

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-7.2	-4.5	-	52.19

Futura Medical Share Discussion Threads

Showing 16851 to 16872 of 16875 messages

Chat Pages: 675 674 673 672 671 670 669 668 667 666 665 664 Older

Date	Subject	Author	Discuss
18/6/2019 17:01	Good old Grannypants always knows best.	j777j	Read Full Thread Reply
17/6/2019 14:33	As my dear old gran used to tell me "all good things come to those that wait"	ragnarr	Read Full Thread Reply
17/6/2019 13:27	Simply need US bio fund or two onboard and the shares will rerate.	j777j	Read Full Thread Reply
17/6/2019 12:19	Liberum's figures are ultra conservative and that simply amplifies the value here.	j777j	Read Full Thread Reply
17/6/2019 11:56	Thanks J777J.	rrr	Read Full Thread Reply
17/6/2019 11:47	Liberum "The multi-billion dollar market for erectile dysfunction (ED) therapies continues to be dominated by PDE-5 inhibitors, despite a slow onset of action and negative side-effects. We believe Futura’s MED2005 addresses these issues and expect positive P3 data in December. Our confidence is driven by compelling P2 data, a non-binary set of potential outcomes, and a rock-solid safety profile. With a market cap of just £50m vs a peak sales potential of c.£500m, we think the market misses this low risk potential. BUY." "Key catalyst due by Dec 2019 Unlike with most drug discovery businesses, there is not long to wait for the key catalyst, with the headline P3 data due by December. This could drive >500% upside." Yes >500% upside!! "Liberum view: Headline data from FM57 is due by the end of December 2019, which is the key catalyst for the shares. This data alone should be enough to secure a significant outlicensing agreement, but more importantly de-risk the confirmatory second P3 study." "We have not provided much detail on potential competition in the pipeline, as frankly we do not see any at this stage."	j777j	Read Full Thread Reply
17/6/2019 11:34	Just a game of patience here, happy holding.. chart looks good though! One on the move, outdoors be under valued too (C4XD) dyor as usual	ny boy	Read Full Thread Reply
17/6/2019 09:49	>>>martinelwick You can download the note from Research tree https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical	timbo003	Read Full Thread Reply
17/6/2019 08:46	Hi can you provide the link.	martinelwick	Read Full Thread Reply
17/6/2019 08:18	Liberum 60p price target fair value and 137p high end	j777j	Read Full Thread Reply
17/6/2019 08:10	Bullish research report from Liberum today."High probability of success,low valuation......"	j777j	Read Full Thread Reply
12/6/2019 15:18	I always blame my partner !	mikethebike4	Read Full Thread Reply
12/6/2019 08:51	Down to Liberum finding realInstitutional support.	wantage	Read Full Thread Reply
12/6/2019 02:57	The repartition is vapid.	glavey	Read Full Thread Reply
11/6/2019 11:16	Between 8 aug 2016 and 5 sep 2016,the share price went from 21p to 80p on positive news regarding the med gel. Can have quite some moves.	j777j	Read Full Thread Reply
11/6/2019 10:57	Needs some decent new US investors onboard. The rating Fum gets here is minuscule to how it would be valued stateside,for a co with so much potential. Smaller caps in general are cheapest they have been for decades.	j777j	Read Full Thread Reply
11/6/2019 08:34	The pond is shrinking these days, I know a few traders in NYC that are buying into U.K. equities as the exchange rate is so favorable, they have taken the view UK equities are trading at a big discount.	ny boy	Read Full Thread Reply
11/6/2019 08:12	I note the author of the Guardian article is a regular contributor to the New York Times. It would be nice if the article makes it across the pond.	j777j	Read Full Thread Reply
11/6/2019 07:17	They simply need to trumpet the investment case. Awaiting UK regulatory approval for the first pain gel product. Med2005 In commercial negotiations with licencees.. 15% royalties are forecast. Total upfront and milestone payments for EU and USA $90 million are forecast. Over $1billion peak sales are forecast. First major ED development in 20 years. 300 million men suffer ED and that is climbing rapidly as populations age and obesity and unhealthy living are on the rise too. Futura have a topical product that is fast acting.Completely bypassing any risks incurred by swallowing a pill like viagra.	j777j	Read Full Thread Reply
11/6/2019 05:05	Maybe they should try ramping instead, that seems to have been more successful of late.	glavey	Read Full Thread Reply
10/6/2019 18:27	Well hopefully like the rest of us they will learn.	j777j	Read Full Thread Reply
10/6/2019 16:43	'management' is not Futura's forte !	mikethebike4	Read Full Thread Reply

Chat Pages: 675 674 673 672 671 670 669 668 667 666 665 664 Older